



UNIVERCELLS
Technologies™
By Donaldson

An innovative platform for cost-effective decentralized manufacturing

Mathias Garny, General Manager


DCVMN AGM | Session 9 Innovations in Science & Technology | September 21, 2023

©2023 Univercells Technologies. All Rights Reserved.

| The next evolution of biomanufacturing

Traditional vaccine manufacturing models rely on scale, which **will not directly apply to decentralized/regional manufacture**

Impact of scale on process economics




1) Generic adenovirus process is stainless steel STR, 1E14vp/L, 40% DSP yield , 1E11vp/dose

An innovative vaccine manufacturing technology combining **process intensification** to **reduce volumes** and **integration of multiple unit steps** into a single platform



A technology platform specifically designed to address the CAPEX barrier and achieve cost-effective production in a context of local/regional manufacturing

Increased cell concentration and productivity delivering millions of doses




Doses/year in NevoLine / scale-X nitro 600m²

Vero	rVSV-LASV	684 million
MRC-5	Rubella	300 million
Vero	sIPV	>10 million
Vero	VSV-Ebola	>6 million

Reduced COGS (lower operational volumes, manual operations)



Reduced facility CAPEX with lower cleanroom footprint





UNIVERCELLS
Technologies™
By Donaldson

Thank you
for your attention
www.univercellstech.com

| The next evolution of biomanufacturing

Univercells is a trademark or registered trademark of Univercells S.A. exclusively licensed to Univercells Technologies S.A.. Univercells Technologies, the Univercells Technologies logo, scale-X, NevoLine are trademarks or registered trademarks of Univercells Technologies. All other trademarks are the property of their respective owners